The dual-hormone idea behind CagriSema CagriSema is a fixed-dose combination of cagrilintide 2.4 mg, a long-acting amylin analogue, and semaglutide 2.4 mg, the GLP-1 receptor agonist already familiar as the active ingredient in Wegovy and Ozempic
Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial
Cellular senescence and senolytics: the path to the clinic
These powerful injections can provide incredible health benefits, but they require the skilled hands of a trained healthcare professional to ensure you get the best results while staying safe
Anikster Y, Lacbawan F, Brantly M, Gochuico BL, Avila NA, Travis W, Gahl WA (2001) Pulmonary dysfunction in adults with nephropathic cystinosis